388 related articles for article (PubMed ID: 23166301)
1. TAK1 is essential for osteoclast differentiation and is an important modulator of cell death by apoptosis and necroptosis.
Lamothe B; Lai Y; Xie M; Schneider MD; Darnay BG
Mol Cell Biol; 2013 Feb; 33(3):582-95. PubMed ID: 23166301
[TBL] [Abstract][Full Text] [Related]
2. Tumor necrosis factor-alpha (TNF) stimulates RANKL-induced osteoclastogenesis via coupling of TNF type 1 receptor and RANK signaling pathways.
Zhang YH; Heulsmann A; Tondravi MM; Mukherjee A; Abu-Amer Y
J Biol Chem; 2001 Jan; 276(1):563-8. PubMed ID: 11032840
[TBL] [Abstract][Full Text] [Related]
3. TRAF2 is essential for TNF-alpha-induced osteoclastogenesis.
Kanazawa K; Kudo A
J Bone Miner Res; 2005 May; 20(5):840-7. PubMed ID: 15824857
[TBL] [Abstract][Full Text] [Related]
4. TAK1, but not TAB1 or TAB2, plays an essential role in multiple signaling pathways in vivo.
Shim JH; Xiao C; Paschal AE; Bailey ST; Rao P; Hayden MS; Lee KY; Bussey C; Steckel M; Tanaka N; Yamada G; Akira S; Matsumoto K; Ghosh S
Genes Dev; 2005 Nov; 19(22):2668-81. PubMed ID: 16260493
[TBL] [Abstract][Full Text] [Related]
5. Protein Kinase-Mediated Decision Between the Life and Death.
Engin A
Adv Exp Med Biol; 2021; 1275():1-33. PubMed ID: 33539010
[TBL] [Abstract][Full Text] [Related]
6. The scaffold protein RACK1 mediates the RANKL-dependent activation of p38 MAPK in osteoclast precursors.
Lin J; Lee D; Choi Y; Lee SY
Sci Signal; 2015 Jun; 8(379):ra54. PubMed ID: 26038599
[TBL] [Abstract][Full Text] [Related]
7. Adenosine A1 receptor regulates osteoclast formation by altering TRAF6/TAK1 signaling.
He W; Cronstein BN
Purinergic Signal; 2012 Jun; 8(2):327-37. PubMed ID: 22311477
[TBL] [Abstract][Full Text] [Related]
8. Receptor activator of NF-kappaB ligand (RANKL) activates TAK1 mitogen-activated protein kinase kinase kinase through a signaling complex containing RANK, TAB2, and TRAF6.
Mizukami J; Takaesu G; Akatsuka H; Sakurai H; Ninomiya-Tsuji J; Matsumoto K; Sakurai N
Mol Cell Biol; 2002 Feb; 22(4):992-1000. PubMed ID: 11809792
[TBL] [Abstract][Full Text] [Related]
9. 2-Methoxystypandrone represses RANKL-mediated osteoclastogenesis by down-regulating formation of TRAF6-TAK1 signalling complexes.
Chiou WF; Liao JF; Huang CY; Chen CC
Br J Pharmacol; 2010 Sep; 161(2):321-35. PubMed ID: 20735418
[TBL] [Abstract][Full Text] [Related]
10. The Role of TAK1 in RANKL-Induced Osteoclastogenesis.
Jianwei W; Ye T; Hongwei W; Dachuan L; Fei Z; Jianyuan J; Hongli W
Calcif Tissue Int; 2022 Jul; 111(1):1-12. PubMed ID: 35286417
[TBL] [Abstract][Full Text] [Related]
11. Ablation of Tak1 in osteoclast progenitor leads to defects in skeletal growth and bone remodeling in mice.
Qi B; Cong Q; Li P; Ma G; Guo X; Yeh J; Xie M; Schneider MD; Liu H; Li B
Sci Rep; 2014 Nov; 4():7158. PubMed ID: 25418008
[TBL] [Abstract][Full Text] [Related]
12. Caffeic acid 3,4-dihydroxy-phenethyl ester suppresses receptor activator of NF-κB ligand–induced osteoclastogenesis and prevents ovariectomy-induced bone loss through inhibition of mitogen-activated protein kinase/activator protein 1 and Ca2+–nuclear factor of activated T-cells cytoplasmic 1 signaling pathways.
Wu X; Li Z; Yang Z; Zheng C; Jing J; Chen Y; Ye X; Lian X; Qiu W; Yang F; Tang J; Xiao J; Liu M; Luo J
J Bone Miner Res; 2012 Jun; 27(6):1298-1308. PubMed ID: 22337253
[TBL] [Abstract][Full Text] [Related]
13. Tumor necrosis factor alpha stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction.
Kobayashi K; Takahashi N; Jimi E; Udagawa N; Takami M; Kotake S; Nakagawa N; Kinosaki M; Yamaguchi K; Shima N; Yasuda H; Morinaga T; Higashio K; Martin TJ; Suda T
J Exp Med; 2000 Jan; 191(2):275-86. PubMed ID: 10637272
[TBL] [Abstract][Full Text] [Related]
14. Osteoclast differentiation requires TAK1 and MKK6 for NFATc1 induction and NF-kappaB transactivation by RANKL.
Huang H; Ryu J; Ha J; Chang EJ; Kim HJ; Kim HM; Kitamura T; Lee ZH; Kim HH
Cell Death Differ; 2006 Nov; 13(11):1879-91. PubMed ID: 16498455
[TBL] [Abstract][Full Text] [Related]
15. Pim-1 regulates RANKL-induced osteoclastogenesis via NF-κB activation and NFATc1 induction.
Kim K; Kim JH; Youn BU; Jin HM; Kim N
J Immunol; 2010 Dec; 185(12):7460-6. PubMed ID: 21068407
[TBL] [Abstract][Full Text] [Related]
16. Regulation of RANKL-induced osteoclastogenesis by TGF-β through molecular interaction between Smad3 and Traf6.
Yasui T; Kadono Y; Nakamura M; Oshima Y; Matsumoto T; Masuda H; Hirose J; Omata Y; Yasuda H; Imamura T; Nakamura K; Tanaka S
J Bone Miner Res; 2011 Jul; 26(7):1447-56. PubMed ID: 21305609
[TBL] [Abstract][Full Text] [Related]
17. Lysine 63-linked polyubiquitination of TAK1 at lysine 158 is required for tumor necrosis factor alpha- and interleukin-1beta-induced IKK/NF-kappaB and JNK/AP-1 activation.
Fan Y; Yu Y; Shi Y; Sun W; Xie M; Ge N; Mao R; Chang A; Xu G; Schneider MD; Zhang H; Fu S; Qin J; Yang J
J Biol Chem; 2010 Feb; 285(8):5347-60. PubMed ID: 20038579
[TBL] [Abstract][Full Text] [Related]
18. BSP and RANKL induce osteoclastogenesis and bone resorption synergistically.
Valverde P; Tu Q; Chen J
J Bone Miner Res; 2005 Sep; 20(9):1669-79. PubMed ID: 16059638
[TBL] [Abstract][Full Text] [Related]
19. Receptor activator of NF-kappa B ligand stimulates recruitment of SHP-1 to the complex containing TNFR-associated factor 6 that regulates osteoclastogenesis.
Zhang Z; Jimi E; Bothwell AL
J Immunol; 2003 Oct; 171(7):3620-6. PubMed ID: 14500659
[TBL] [Abstract][Full Text] [Related]
20. NF-kappaB p50 and p52 expression is not required for RANK-expressing osteoclast progenitor formation but is essential for RANK- and cytokine-mediated osteoclastogenesis.
Xing L; Bushnell TP; Carlson L; Tai Z; Tondravi M; Siebenlist U; Young F; Boyce BF
J Bone Miner Res; 2002 Jul; 17(7):1200-10. PubMed ID: 12096833
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
